KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Cash from Financing Activities (2016 - 2025)

Ionis Pharmaceuticals has reported Cash from Financing Activities over the past 17 years, most recently at $591.2 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $591.2 million for Q4 2025, up 1440.05% from a year ago — trailing twelve months through Dec 2025 was $675.8 million (up 41.37% YoY), and the annual figure for FY2025 was $675.8 million, up 41.37%.
  • Cash from Financing Activities for Q4 2025 was $591.2 million at Ionis Pharmaceuticals, up from $81.2 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for IONS hit a ceiling of $591.2 million in Q4 2025 and a floor of -$62.5 million in Q4 2021.
  • Median Cash from Financing Activities over the past 5 years was $2.0 million (2022), compared with a mean of $99.4 million.
  • Peak annual rise in Cash from Financing Activities hit 11713.83% in 2023, while the deepest fall reached 1859.38% in 2023.
  • Ionis Pharmaceuticals' Cash from Financing Activities stood at -$62.5 million in 2021, then increased by 18.36% to -$51.0 million in 2022, then skyrocketed by 179.82% to $40.7 million in 2023, then tumbled by 208.33% to -$44.1 million in 2024, then soared by 1440.05% to $591.2 million in 2025.
  • The last three reported values for Cash from Financing Activities were $591.2 million (Q4 2025), $81.2 million (Q3 2025), and $1.2 million (Q2 2025) per Business Quant data.